<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Postgrad Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Postgrad Med</journal-id>
      <journal-id journal-id-type="publisher-id">JPGM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Postgraduate Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-3859</issn>
      <issn pub-type="epub">0972-2823</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25766353</article-id>
      <article-id pub-id-type="pmc">4943427</article-id>
      <article-id pub-id-type="publisher-id">JPGM-61-137</article-id>
      <article-id pub-id-type="doi">10.4103/0022-3859.150907</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Snippet</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with <italic>Tp53</italic> gene deletion</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gupta</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parihar</surname>
            <given-names>M</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yadav</surname>
            <given-names>AK</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chakrapani</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India</aff>
      <aff id="aff2"><label>1</label>Department of Clinical Hematology, Tata Medical Center, Kolkata, West Bengal, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mayur Parihar, E-mail: <email xlink:href="mayurparihar@gmail.com">mayurparihar@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Apr-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>61</volume>
      <issue>2</issue>
      <fpage>137</fpage>
      <lpage>138</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; 2015 Journal of Postgraduate Medicine</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Concurrent manifestation of a myeloid and lymphoid neoplasm is a rare occurrence and is reported in less than 1% of the cases.[<xref rid="ref1" ref-type="bibr">1</xref>]</p>
    <p>A 57 year old patient presented with weakness, lymphadenopathy and hepatosplenomegaly, with a WBC count of 1,51,500/<italic>&#x3BC;</italic>L and 92% lymphocytes. Immunophenotyping confirmed the diagnosis of CLL with the neoplastic cells expressing CD19,CD5, CD23, CD79b and CD20. Fluorescence <italic>in situ</italic> hybridization (FISH) analysis on lymphocytes enriched by lipopolysaccharide-stimulated culture (LSC) showed TP53 deletion in 42% of the interphase cells. On treatment with single agent cyclophosphamide, 24 months post-diagnosis he presented with features of an evolving myeloproliferative neoplasm with a total count of 52,600/&#x3BC;L and a differential count that showed11% immature myeloid precursors,4% basophils and 40% lymphocytes. FISH done on peripheral blood using BCR-ABL1 dual-color dual fusion probe showed BCR-ABL1 fusion positivity in 34% of cells with an atypical single fusion signal pattern (1F2G1R). FISH analysis on lymphocytes enriched by LSC showed TP53 deletion in 15% of the cells. Conventional cytogenetic analysis of metaphases from un-stimulated overnight bone marrow cultures showed a t (9;15)(q34;q22) in 38 of the 40 metaphases with no morphological evidence of a Ph chromosome or deletion of the short arm of chromosome 17 (17p) [Figure <xref ref-type="fig" rid="F1">1a</xref> and <xref ref-type="fig" rid="F1">b</xref>].</p>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>(a) GTG banded processed metaphase spread from LPS stimulated bone marrow cultures. (b) GTG banded karyogram spread from LPS-stimulated bone marrow cultures showing t(9;15), marked with small arrows, and both normal chromosome 22. Chromosome 17 appears normal. (c) Inverted DAPI FISH image of the same matched metaphase as in <xref ref-type="fig" rid="F1">Figure 1a</xref> using BCR-ABL1 probe from Vysis, Abbott, showing BCR-ABL1 fusion signal located on chromosome 9 instead of chromosome 22. Red signal (ABL1) on normal chromosome 9, fusion signal on involved chromosome 9 and two green signals (BCR) on normal chromosome 22. (d) FISH done on LPS stimulated bone marrow cultures using TP53 probe from Vysis, Abbott, and showing 2 green 1red signal pattern indicating deletion of the <italic>TP53</italic> gene in the interphases only</p>
      </caption>
      <graphic xlink:href="JPGM-61-137-g001"/>
    </fig>
    <p>The matched metaphase FISH confirmed the presence of BCR-ABL1fusion, located on derivative chromosome 9 instead of chromosome 22 with green signals on both normal chromosome 22 and one red signal on the normal chromosome 9 (1F2G1R) [<xref ref-type="fig" rid="F1">Figure 1c</xref>]. Quantitative polymerase chain reaction done on the bone marrow aspirate sample showed the presence of p210 (e13a2) fusion transcript confirming the diagnosis of CML. The patient was started on chlorambucil (author give dose) and 400mg of Imatinib per day. Fifteen months post imatinib, the patient remains in complete cytogenetic remission of the CML clone (FISH negative), with persistent CLL clone, the <italic>TP53</italic>gene deletion being present in 23% of the cells [<xref ref-type="fig" rid="F1">Figure 1d</xref>]. Only ten cases of sequential occurrence of CML following CLL have been described in literature. The postulated causes for this are oncogenic effect of chemotherapeutic agents, (cyclophosphamide in the present case), immunodeficiency associated with CLL, defective stem cell pool, age-related accumulation of genetic defects or a common leukemogenic event.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] Secondary CML developing after CLL usually shows a favorable response to Imatinib.[<xref rid="ref4" ref-type="bibr">4</xref>]</p>
    <p>Our case, besides adding on to the series of CML developing in a diagnosed case of CLL and aberrant location of the <italic>BCR-ABL1</italic> fusion gene on chromosome 9 instead of chromosome 22, also provides evidence for separate clonal origin of these neoplasms. Imatinib maintains its therapeutic effectiveness in controlling the CML clone in such an unusual setting though with no effect on CLL clone. The case also emphasizes and reiterates the fact that FISH and karyotyping are complementary to each other and so should be judiciously used together to arrive at a correct diagnosis.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laurenti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tarnani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nichele</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ciolli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cortelezzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Forconi</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience</article-title>
          <source>Am J Hematol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>1007</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">21953617</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Arena</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gemei</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luciano</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>D&#x2019;Auria</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Deaglio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Statuto</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: Two different genomic events and a common treatment?</article-title>
          <source>J ClinOncol</source>
          <year>2012</year>
          <volume>30</volume>
          <fpage>e327</fpage>
          <lpage>30</lpage>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Royle</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Baade</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Joske</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Girschik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fritschi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: A population-based study</article-title>
          <source>Br J Cancer</source>
          <year>2011</year>
          <volume>105</volume>
          <fpage>1076</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">21847118</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhagavathi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borromeo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Crisan</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Case report and literature review: A rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia</article-title>
          <source>Ann Clin Lab Sci</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>405</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">18988937</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
